Bifogade filer
20251010 ViroGates Publication Of Offer Document
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company Announcement no. 12/2025 (October 10, 2025)
BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, shares an announcement it has received from suPAR Remedy, LLC (the “Offeror”) regarding the recently announced public tender offer to the shareholders of ViroGates for shares in the Company (the "Tender Offer").
In continuation of the announcement on Wednesday, cf. Company Announcement No. 11 of 8 October 2025, ViroGates has today received the attached announcement from the Offeror, referring to the terms of the offer described in the Tender Offer document.
The Offer Document and the announcement are available on ViroGates’ website here.
For more information about the Tender Offer, please contact:
Jakob Knudsen
CEO, ViroGates A/S
jk@ViroGates.com
+45 22 26 13 55
Questions pertaining specifically to the Offeror or the Tender Offer may be referred to:
Tayla Martin
tayla@remedyventures.com
Who will be answering questions on behalf of the Offeror.
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation in health clinics and improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.
The Company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About the Offeror
The Offeror is an investment vehicle formed for the purpose of holding shares in ViroGates. In October 2024, ViroGates and suPAR Health LLC signed an exclusive US distribution agreement for certain of ViroGates' proprietary products. Both suPAR Health LLC and the Offeror are wholly owned subsidiaries of Remedy Ventures 2, LLC, a venture studio and investment vehicle based in the United States managed by a team of seasoned United States healthcare entrepreneurs. Remedy Venture 2, LLC, is 100% owned by Matt Wiggins, who is also Managing Partner of the Offeror.
The products enable testing for soluble urokinase plasminogen activator receptor (suPAR), a biomarker for chronic inflammation. Since then, suPAR Health LLC has been actively exploring strategies to launch suPAR blood tests in the United States. The mission of suPAR Health LLC is to make suPAR a recognized biomarker across the United States, betting on widespread adoption through awareness campaigns targeted at clinicians and individuals alike. To achieve this, suPAR Health LLC is working to:
Comply with state-by-state regulations for diagnostic testing, while ensuring the highest standards of safety and effectiveness.
Expand market opportunities in the burgeoning field of chronic inflammation diagnostics, which is gaining traction as a key area of clinical and personal health management.